Holen Sie sich die Stockscreener-App
3.08
2.84%
-0.09
Handel nachbörslich:
3.22
0.14
+4.55%
Schlusskurs vom Vortag:
$3.17
Offen:
$3.19
24-Stunden-Volumen:
1.04M
Relative Volume:
1.15
Marktkapitalisierung:
$207.47M
Einnahmen:
$488.00K
Nettoeinkommen (Verlust:
$-41.44M
KGV:
-3.3118
EPS:
-0.93
Netto-Cashflow:
$-31.47M
1W Leistung:
+15.79%
1M Leistung:
+27.80%
6M Leistung:
-24.51%
1J Leistung:
-21.13%
1-Tages-Spanne:
$3.07
$3.30
1-Wochen-Bereich:
$2.64
$3.30
52-Wochen-Spanne:
$1.90
$4.99
Cardiff Oncology Inc Stock (CRDF) Company Profile
Firmenname
Cardiff Oncology Inc
Sektor
Branche
Telefon
858-952-7570
Adresse
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Vergleichen Sie CRDF mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
3.08 | 213.53M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Eingeleitet | Noble Capital Markets | Outperform |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2025-06-24 | Eingeleitet | Jefferies | Hold |
| 2024-09-06 | Eingeleitet | Craig Hallum | Buy |
| 2022-01-05 | Eingeleitet | William Blair | Outperform |
| 2021-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-09 | Fortgesetzt | Maxim Group | Buy |
| 2020-10-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-08 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
Is Cardiff Oncology Inc. stock a buy for dividend growthJuly 2025 Action & Long Hold Capital Preservation Tips - ulpravda.ru
Aug Wrap: How Cardiff Oncology Inc XE7C stock reacts to Fed tightening2025 Breakouts & Breakdowns & Fast Gain Stock Tips - moha.gov.vn
How Cardiff Oncology Inc. (XE7C) stock reacts to Fed tighteningRisk Management & Stepwise Swing Trade Plans - ulpravda.ru
Equities Analysts Issue Forecasts for CRDF Q4 Earnings - Defense World
Can Cardiff Oncology Inc. stock double in next 5 yearsDividend Growth Stocks & Today’s Picks, Tomorrow’s Winners - ulpravda.ru
What is Noble Financial’s Estimate for CRDF FY2025 Earnings? - Defense World
Analysts Offer Predictions for CRDF FY2025 Earnings - MarketBeat
Cardiff Oncology stock initiated with Outperform rating by Noble Capital - Investing.com Australia
Noble Financial Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology Inc. (CRDF) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Investors Purchase High Volume of Call Options on Cardiff Oncology (NASDAQ:CRDF) - Defense World
Cardiff Oncology (FRA:XE7C) EV-to-OCF : -3.04 (As of Dec. 24, 2025) - GuruFocus
Stock Traders Purchase High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - MarketBeat
Flputnam Investment Management Co. Purchases 543,370 Shares of Cardiff Oncology, Inc. $CRDF - MarketBeat
Why analysts raise outlook for Cardiff Oncology Inc. (XE7C) stockTrade Analysis Report & Precise Swing Trade Entry Alerts - Улправда
3 Penny Stocks With At Least $100M Market Cap - simplywall.st
Short Covering: How analysts revise price targets for ConAgra Brands Inc stockPrice Action & Low Risk Profit Maximizing Plans - moha.gov.vn
Cardiff Oncology Earnings Notes - Trefis
Will Cardiff Oncology Inc. stock benefit from green energy trendsQuarterly Portfolio Summary & Verified Technical Trade Signals - Улправда
Quarterly Earnings: Will SIFYR stock continue dividend increasesMarket Activity Summary & AI Forecasted Entry and Exit Points - moha.gov.vn
Is Cardiff Oncology Inc. stock affected by interest rate hikesWeekly Profit Summary & Weekly Breakout Watchlists - Улправда
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.83 Average Price Target from Analysts - Defense World
Published on: 2025-12-20 05:10:29 - Улправда
Institution Moves: Will Cardiff Oncology Inc. stock benefit from green energy trendsCPI Data & Daily Profit Focused Screening - Улправда
Aug Spikes: Is Cardiff Oncology Inc. stock affected by interest rate hikes2025 Retail Activity & Safe Swing Trade Setup Alerts - Улправда
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Cardiff Oncology (STU:XE7C) EV-to-FCF : -2.30 (As of Dec. 18, 2025) - GuruFocus
Can Cardiff Oncology Inc. stock sustain revenue growthJuly 2025 Momentum & Consistent Return Investment Signals - Улправда
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Rating of "Hold" by Brokerages - MarketBeat
Operating cash flow per share of Cardiff Oncology, Inc. – LSX:A2P4GU - TradingView — Track All Markets
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Zacks Small Cap Weighs in on CRDF FY2025 Earnings - Defense World
What drives Cardiff Oncology Inc stock priceSmall Cap Stock Opportunities & Free Daily Stock Hotspot Analysis - earlytimes.in
Cardiff Oncology CRDF US - Smartkarma
FY2025 Earnings Forecast for CRDF Issued By Zacks Small Cap - MarketBeat
A new trading data show Cardiff Oncology Inc (CRDF) is showing positive returns. - setenews.com
Institutions profited after Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap rose US$19m last week but retail investors profited the most - Yahoo Finance
CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response - Zacks Small Cap Research
Cardiff Presents Phase 1 Data Of Onvensertib In Chronic Myelomonocytic Leukemia At ASH 2025 - Nasdaq
Cardiff oncology reports positive results for onvansertib in leukemia trial - Investing.com
Cardiff oncology reports positive results for onvansertib in leukemia trial By Investing.com - Investing.com India
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 - The Manila Times
Cardiff Oncology Announces Clinical Data from - One News Page
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference - The Manila Times
Is Cardiff Oncology Inc. stock a contrarian buy2025 Key Highlights & Technical Pattern Based Signals - Newser
How Cardiff Oncology Inc. (XE7C) stock stacks up against competitorsMarket Risk Report & Low Volatility Stock Recommendations - Newser
Will Cardiff Oncology Inc. (XE7C) stock announce a stock splitAnalyst Upgrade & Technical Pattern Based Signals - Newser
Finanzdaten der Cardiff Oncology Inc-Aktie (CRDF)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):